Estrogen receptors (ER) are cellular proteins that bind estrogens with a high affinity and specificity. They are a necessary component for estrogen-mediated cellular activity. The presence of progesterone receptors (PR) demonstrates an active ER mechanism for the induction of PR expression. Immunohistochemical staining permits the detection and localization of ER/PR within sections from formalin-fixed, paraffin-embedded tissue. Clinical utilities for the measurement of ER/PR include patient prognosis and patient response to adjuvant endocrine therapy. Individuals with receptor-positive tumors generally have a better prognosis, as indicated by a longer interval to disease recurrence and a longer overall survival, than patients with receptor-negative tumors. Studies have also shown that the determination of receptor status by immunohistochemistry may be useful in predicting patient response to hormonal therapy. HER2/neu (also known as ErbB-2) stands for "Human Epidermal growth factor Receptor 2" and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2/neu has also been designated as CD340 (cluster of differentiation 340) and p185. It is encoded by the ERBB2 gene.
No special preparation is needed for Er Pr Her 2 Neu Immunohistochemistry Biopsy Tissue. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing Er Pr Her 2 Neu Immunohistochemistry Biopsy Tissue. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||The observations depend on the type of cancer detected|